SJBT031026_D1.RNA-Seq
EPN · Spinal EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Spinal EPN
- cancer_type
- EPN
- subtype
- Spinal EPN
- age_years
- 16.28
- e1_e2
- E1
- umap1_2d
- -1.422364397
- umap2_2d
- 2.482913365
- umap1_3d
- -0.234170687
- umap2_3d
- 0.161313158
- umap3_3d
- -0.772847918
- dataset
- EPN-StJude
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Y3G1X98S | Meningioma | — | 0.857 |
| 2 | BS_53CTGDQG | Meningioma | — | 0.846 |
| 3 | SJBT031026_D3.RNA-Seq | EPN | Spinal EPN | 0.844 |
| 4 | BS_49VCQD19 | Neurofibroma | — | 0.842 |
| 5 | BS_9HA238XS | Neurofibroma | — | 0.835 |
| 6 | BS_Q2T9ZRM0 | Meningioma | — | 0.835 |
| 7 | BS_NDRDM2A9 | Neurofibroma | — | 0.834 |
| 8 | BS_RQSKD7PN | MPNST | — | 0.832 |
| 9 | BS_7H4RFCW9 | low-grade glioma | — | 0.831 |
| 10 | BS_THSPSG2Z | Meningioma | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |